Bio + Health

Regulation as a Catalyst with Jonathan Bush and Chris Severn

Jonathan Bush, Colin Rom, Chris Severn, Julie Yoo, Kris Tatiossian, and Olivia Webb Posted June 25, 2024

Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, joined Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.

We’ve long believed that regulatory change can be a catalyst for company creation. In this episode, Jonathan and Chris detail how that was true for them. They also outline a few key takeaways for founders hoping to leverage regulatory change themselves.

Policy can be shaped—but that often requires relationship-building

As Chris and Jonathan both told us during the episode, policymakers often don’t get to hear from technologists and founders; instead, incumbents, like health systems and pharmaceutical companies, are often front and center. But that doesn’t mean policymakers aren’t open to hearing from entrepreneurs. When Chris and his cofounder Adam found an online notice for a public forum with key government agencies during the comment period for what became the Hospital Price Transparency Rule, they reached out to the agencies and asked if they’d be interested in speaking to founders. The agencies agreed, and Chris and Adam got to help shape the eventual rule. Jonathan also shared how he similarly contributed to the shaping of the 21st Century Cures Act.

Regulations change over time

Even once a law is passed, how that law is interpreted and implemented often evolves as the impacted parties gain more experience and provide feedback to regulators. As Colin points out during the episode, that feedback to policymakers most often stems from the most vocal constituents, which in healthcare are usually the biggest employers in a given district (typically health systems or other large corporations). But they don’t as often hear from founders about how a specific rule might affect innovation or patient care. Being able to explain clearly the downstream effects can make a big difference as the policy continues to be shaped (often a long process!).

And again, relationships matter. As Jonathan notes, “One of the things that is interesting about the way Washington works is that when a congressman says, we want to work with industry. A) they mean it, they genuinely do. But B) they mean people who have Washington offices. So basically, they don’t mean 99 percent of the new products and new companies in the world.” This doesn’t mean you have to have a Washington office. But it does mean that you have to build relationships like you do.

Policy can have unintended consequences for startups, both good and bad

Perhaps the opposite of regulation as a catalyst is regulatory capture. Regulatory capture can be used by incumbents to, as Jonathan puts it on the episode, “close the airlock” behind them. By enacting onerous regulations or requirements, policy can be used to keep smaller, more innovative companies out of the field. Companies should respond by building their relationships in DC, keeping an eye on potential changes that could affect them, and, as Chris says, continually earning their “right to win,” the x-factor that keeps the company ahead of the competition. Which brings us to the last point to highlight…

Regulation can be a catalyst…but creating durable businesses requires much more

While companies like Turquoise and Zus can take advantage of the opening in the market that is created by a new rule, regulation, or policy, it takes far more to create a differentiated, durable, and scalable business on top of that. Jonathan talks about how companies need to create enough value to fight past the “performative compliance” that incumbents often put on display, in which they do the minimal amount of work to check the box on regulatory compliance. Chris also weighed in on how he was able to turn his product into a competitive advantage for his customers, in addition to helping them comply with the transparency rules. Even though both founders admit that their companies probably wouldn’t exist if not for the relevant rules and regulations, they both recognize that those rules and regs were a necessary but not sufficient justification for them to decide that it was their time to build.

About the Contributors
Raising Health

Biology and the state of healthcare are undergoing radical shifts.
Raising Health delves into dialogues with scientists, technologists, founders, builders, leaders, and visionaries as they explore how AI, engineering, and technology elevate health to new heights and create a system of enduring health for all.

Learn More
Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Bio + Health

Streamlining the Patient Referrals Chain with Trey Holterman

David Haber, Trey Holterman, Jay Rughani, Kris Tatiossian, and Olivia Webb
Bio + Health

From Chaos to Clarity in Data with Malinka Walaliyadde

Malinka Walaliyadde, Julie Yoo, Olivia Webb, and Kris Tatiossian
Bio + Health

Superaging with Eric Topol

Eric Topol and Vijay Pande
Bio + Health

What Super Agers Reveal About Preventing Disease

Eric Topol and Vijay Pande
Bio + Health

Fueling Innovation with Data with Arif Nathoo

Arif Nathoo, Jorge Conde, Jay Rughani, Olivia Webb, and Kris Tatiossian

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.